OncoMatch/Clinical Trials/NCT04840264
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Is NCT04840264 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Docetaxel and Oxaliplatin for metastatic gastric adenocarcinoma.
Treatment: Docetaxel · Oxaliplatin · Fluorouracil — This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel obstruction.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Gastric Cancer
Esophageal Carcinoma
Ovarian Cancer
Biomarker criteria
Excluded: HER2 (ERBB2) amplification
HER-2 amplification or overexpression
Excluded: HER2 (ERBB2) overexpression
HER-2 amplification or overexpression
Excluded: MMR expression deletion
mismatch repair protein expression deletion (dMMR)
Excluded: MSI high
genetic testing suggestive of high microsatellite instability (MSI-H)
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Cannot have received: combination regimen containing all the study drugs (docetaxel, oxaliplatin, 5-fluorouracil)
treated by a combination regimen containing all the study drugs
Lab requirements
Blood counts
Hb≥60g/L, WBC ≥4×10E9/L, ANC≥2×10E9/L, PLT≥100×10E9/L
Kidney function
Cr≤ Upper Normal Limit(UNL)
Liver function
Tbil≤1.5 UNL, AST≤1.5 UNL, ALT≤1.5 UNL, ALP≤1.5 UNL
Hb≥60g/L, WBC ≥4×10E9/L, ANC≥2×10E9/L，PLT≥100×10E9/L; Cr≤ Upper Normal Limit(UNL); Tbil≤1.5 UNL,AST≤1.5 UNL, ALT≤1.5 UNL, ALP≤1.5 UNL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04840264 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior combination regimen containing all the study drugs disqualifies patients from enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 amplification is an exclusion criterion.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages